Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Blood Pressure
  • Carcinoma, Renal Cell
  • Hypertension
  • Indoles
  • Kidney Neoplasms
  • Pyrroles

abstract

  • In patients with metastatic renal cell carcinoma, sunitinib-associated HTN is associated with improved clinical outcomes without clinically significant increases in HTN-associated adverse events, supporting its viability as an efficacy biomarker.

publication date

  • May 4, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3086879

Digital Object Identifier (DOI)

  • 10.1093/jnci/djr128

PubMed ID

  • 21527770

Additional Document Info

start page

  • 763

end page

  • 73

volume

  • 103

number

  • 9